Therapeutic role of miR-19a/b protection from influenza virus infection in patients with coronary heart disease.

Patients with pre-existing medical conditions are at a heightened risk of contracting severe acute respiratory syndrome (SARS), SARS-CoV-2, and influenza viruses, which can result in more severe disease progression and increased mortality rates. Nevertheless, the molecular mechanism behind this phenomenon remained largely unidentified. Here, we found that microRNA-19a/b (miR-19a/b), which is a constituent of the miR-17-92 cluster, exhibits reduced expression levels in patients with coronary heart disease in comparison to healthy individuals. The downregulation of miR-19a/b has been observed to facilitate the replication of influenza A virus (IAV). miR-19a/b can effectively inhibit IAV replication by targeting and reducing the expression of SOCS1, as observed in cell-based and coronary heart disease mouse models. This mechanism leads to the alleviation of the inhibitory effect of SOCS1 on the interferon (IFN)/JAK/STAT signaling pathway. The results indicate that the IAV employs a unique approach to inhibit the host's type I IFN-mediated antiviral immune responses by decreasing miR-19a/b. These findings provide additional insights into the underlying mechanisms of susceptibility to flu in patients with coronary heart disease. miR-19a/b can be considered as a preventative/therapy strategy for patients with coronary heart disease against influenza virus infection. © 2024 The Authors.

Citation

Yanan Xing, Lin Chen, Bin Hu, Yi Li, Huan Mai, Gaojian Li, Shuyi Han, Ye Wang, Yanyi Huang, Ying Tian, Wei Zhang, Yan Gao, Hongxuan He. Therapeutic role of miR-19a/b protection from influenza virus infection in patients with coronary heart disease. Molecular therapy. Nucleic acids. 2024 Mar 12;35(1):102149

PMID: 38435118

search → result